Sarepta Therapeutics (SRPT) stock drops as the company faces potential FDA-mandated studies after safety concerns over its ...

While Sarepta has now consented to the FDA’s request to stop selling Elevidys, the company’s brief standoff with the agency ...

As the controversy over the safety of Sarepta Therapeutics’ gene therapies comes to a head, the biotech is standing firm ...

Sarepta (SRPT) plans to continue Elevidys shipments for Duchenne muscular dystrophy, despite FDA request not to do so after ...

Sarepta led investors to believe that its ELEVIDYS therapy was both safe and had potential for approval in wider applications. The Company misled the market about its revenue outlook on ELEVIDYS.

Investors Urged to Contact Levi & Korsinsky for Information Before August 25, 2025 - Sarepta Therapeutics, Inc. (SRPT) ...

NEW YORK, July 12, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 ...

Lost Money on Sarepta Therapeutics, Inc. (SRPT)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky Provided by GlobeNewswire Jul 11, 2025, 1:22:00 PM ...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive ...

The complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Sarepta's gene therapy treatment, ELEVIDYS, posed ...

Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) ELEVIDYS, a prescription gene ...

Robbins LLP Files Class Action Against Sarepta Therapeutics Over ELEVIDYS Deaths. Robbins LLP has filed a securities class action on behalf of investors who purchased shares of Sarepta Therapeutics, ...